ENOCHIAN BIOSCIENCES INC (ENOB) Stock Price & Overview
NASDAQ:ENOB • US29350E1047
Current stock price
The current stock price of ENOB is 0.7 USD. Today ENOB is down by 0%. In the past month the price increased by 47.99%. In the past year, price decreased by -75.52%.
ENOB Key Statistics
- Market Cap
- 40.799M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.00
- Dividend Yield
- N/A
ENOB Stock Performance
ENOB Stock Chart
ENOB Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ENOB. When comparing the yearly performance of all stocks, ENOB is a bad performer in the overall market: 96.77% of all stocks are doing better.
ENOB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ENOB. ENOB may be in some trouble as it scores bad on both profitability and health.
ENOB Earnings
ENOB Forecast & Estimates
ENOB Groups
Sector & Classification
ENOB Financial Highlights
Over the last trailing twelve months ENOB reported a non-GAAP Earnings per Share(EPS) of -2. The EPS decreased by -149.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ENOB Ownership
ENOB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.99 | 369.265B | ||
| AMGN | AMGEN INC | 15.09 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.8 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.56 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.4 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.24 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.81 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.42 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ENOB
Company Profile
Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 11 full-time employees. The company went IPO on 2014-11-18. The firm is focused on developing allogeneic cell and gene therapies to promote stronger immune system responses for long-term or life-long cancer remission in cancers and to treat or cure infectious diseases, such as Human Immunodeficiency Virus (HIV) and Hepatitis B virus (HBV) infection. The Allogeneic Cell Therapy platform has a human immune system, which is designed to recognize the self and destroy otherness or non-self, such as bacteria, viruses and cancer cells. The Company’s product candidates include ENOB-HV-01, which utilizes a cellular- and immunotherapy approach that could provide both preventative and therapeutic vaccines for HIV and ENOB-DC-11, which is a genetically modified allogeneic dendritic cell therapeutic vaccine as product for long-term remission of solid tumors. The company is also exploring ENOB-HV-21, a treatment for HIV with allogeneic natural killer (NK) and gamma delta t-cells (GDT).
Company Info
IPO: 2014-11-18
ENOCHIAN BIOSCIENCES INC
Century City Medical Plaza, 2080 Century City East
Los Angeles CALIFORNIA 90067 US
CEO: Mark Dybul
Employees: 11
Phone: 14539179840.0
ENOCHIAN BIOSCIENCES INC / ENOB FAQ
What does ENOB do?
Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 11 full-time employees. The company went IPO on 2014-11-18. The firm is focused on developing allogeneic cell and gene therapies to promote stronger immune system responses for long-term or life-long cancer remission in cancers and to treat or cure infectious diseases, such as Human Immunodeficiency Virus (HIV) and Hepatitis B virus (HBV) infection. The Allogeneic Cell Therapy platform has a human immune system, which is designed to recognize the self and destroy otherness or non-self, such as bacteria, viruses and cancer cells. The Company’s product candidates include ENOB-HV-01, which utilizes a cellular- and immunotherapy approach that could provide both preventative and therapeutic vaccines for HIV and ENOB-DC-11, which is a genetically modified allogeneic dendritic cell therapeutic vaccine as product for long-term remission of solid tumors. The company is also exploring ENOB-HV-21, a treatment for HIV with allogeneic natural killer (NK) and gamma delta t-cells (GDT).
What is the stock price of ENOCHIAN BIOSCIENCES INC today?
The current stock price of ENOB is 0.7 USD.
Does ENOCHIAN BIOSCIENCES INC pay dividends?
ENOB does not pay a dividend.
What is the ChartMill technical and fundamental rating of ENOB stock?
ENOB has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the market cap for ENOCHIAN BIOSCIENCES INC?
ENOCHIAN BIOSCIENCES INC (ENOB) has a market capitalization of 40.80M USD. This makes ENOB a Nano Cap stock.